MX2021001558A - Inhibidores de itk de pirrolopirimidina. - Google Patents

Inhibidores de itk de pirrolopirimidina.

Info

Publication number
MX2021001558A
MX2021001558A MX2021001558A MX2021001558A MX2021001558A MX 2021001558 A MX2021001558 A MX 2021001558A MX 2021001558 A MX2021001558 A MX 2021001558A MX 2021001558 A MX2021001558 A MX 2021001558A MX 2021001558 A MX2021001558 A MX 2021001558A
Authority
MX
Mexico
Prior art keywords
pyrrolopyrimidine
tki inhibitors
formulas
itk
tki
Prior art date
Application number
MX2021001558A
Other languages
English (en)
Spanish (es)
Inventor
David Anderson
Eric Jacobsen
James Blinn
Susan Hockerman
Richard Heier
Paramita Mukherjee
Original Assignee
Aclaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics Inc filed Critical Aclaris Therapeutics Inc
Publication of MX2021001558A publication Critical patent/MX2021001558A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021001558A 2018-08-10 2019-08-12 Inhibidores de itk de pirrolopirimidina. MX2021001558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862717400P 2018-08-10 2018-08-10
PCT/US2019/046182 WO2020033955A1 (en) 2018-08-10 2019-08-12 Pyrrolopyrimidine itk inhibitors

Publications (1)

Publication Number Publication Date
MX2021001558A true MX2021001558A (es) 2021-04-28

Family

ID=69405523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001558A MX2021001558A (es) 2018-08-10 2019-08-12 Inhibidores de itk de pirrolopirimidina.

Country Status (13)

Country Link
US (4) US11021482B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833350A4 (cg-RX-API-DMAC7.html)
JP (2) JP7591500B2 (cg-RX-API-DMAC7.html)
KR (1) KR102849047B1 (cg-RX-API-DMAC7.html)
CN (2) CN112823005B (cg-RX-API-DMAC7.html)
AU (1) AU2019317625B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002479A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109192A1 (cg-RX-API-DMAC7.html)
IL (1) IL280593A (cg-RX-API-DMAC7.html)
MX (1) MX2021001558A (cg-RX-API-DMAC7.html)
PH (1) PH12021550187A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100525SA (cg-RX-API-DMAC7.html)
WO (1) WO2020033955A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
JP7591500B2 (ja) * 2018-08-10 2024-11-28 アクラリス セラピューティクス,インコーポレイテッド ピロロピリミジンitk阻害剤
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
PH12021552036A1 (en) 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス, インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ip有限責任公司 腸道選擇性jak3抑制劑的投與
KR102560138B1 (ko) * 2020-06-15 2023-07-27 경북대학교 산학협력단 신경교세포 표현형 기반의 siRNA 다중 스크리닝을 통해 선별된 신경교세포 인산화효소의 신경염증 조절 용도
CN114887080B (zh) * 2020-12-08 2023-10-31 深圳瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
CN113350346B (zh) * 2021-06-01 2023-06-27 广西医科大学第一附属医院 长春新碱在预防或治疗心肌纤维化中的应用
KR20230019801A (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN113571191A (zh) * 2021-08-31 2021-10-29 复旦大学附属中山医院 免疫检查点抑制剂相关mace发生风险的预测方法
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
EP4615440A1 (en) * 2022-11-08 2025-09-17 Aclaris Therapeutics, Inc. Pyrrolopyrimidine compositions for treatment of itk mediated conditions
CN116115760A (zh) * 2022-12-15 2023-05-16 浙江大学 Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
AU2024415240A1 (en) * 2023-12-28 2026-07-30 Aclaris Therapeutics, Inc. Crystalline polymorph of an itk inhibitor
AU2024415877A1 (en) * 2023-12-28 2026-07-30 Aclaris Therapeutics, Inc. Methods of synthesizing substituted pyrrolopyrimidine compounds
CN117982685B (zh) * 2024-01-26 2025-05-30 北京大学人民医院 用于骨肉瘤检测的光学分子成像探针及其制备方法和应用
WO2025181247A1 (en) * 2024-02-28 2025-09-04 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2025235366A1 (en) * 2024-05-07 2025-11-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine compositions for treatment of atopic dermatitis

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277954A1 (en) 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2004504259A (ja) 1998-06-30 2004-02-12 パーカー ヒューズ インスティテュート Jak−3インヒビターを用いたc−jun発現の阻害方法
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ3阻害剤
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100105661A1 (en) 2007-01-12 2010-04-29 Astellas Pharma Inc. Condensed pyridine compound
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
AU2016209046A1 (en) * 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CA2984183C (en) 2015-05-01 2021-11-09 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
US10159662B2 (en) 2015-12-11 2018-12-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
RU2714206C1 (ru) 2016-06-30 2020-02-13 Даевунг Фармасьютикал Ко., Лтд. Пиразолопиримидиновые производные в качестве ингибитора киназы
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
JP7591500B2 (ja) * 2018-08-10 2024-11-28 アクラリス セラピューティクス,インコーポレイテッド ピロロピリミジンitk阻害剤
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
PH12021552036A1 (en) 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
WO2021022178A1 (en) 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors

Also Published As

Publication number Publication date
US11021482B2 (en) 2021-06-01
US12297203B2 (en) 2025-05-13
WO2020033955A1 (en) 2020-02-13
CN112823005B (zh) 2024-08-20
EP3833350A1 (en) 2021-06-16
JP7591500B2 (ja) 2024-11-28
US20260035373A1 (en) 2026-02-05
IL280593A (en) 2021-03-25
JP2021534244A (ja) 2021-12-09
CN112823005A (zh) 2021-05-18
BR112021002479A2 (pt) 2021-07-27
US11820775B2 (en) 2023-11-21
US20240132505A1 (en) 2024-04-25
US20200048262A1 (en) 2020-02-13
AU2019317625B2 (en) 2025-02-27
SG11202100525SA (en) 2021-02-25
EP3833350A4 (en) 2022-05-18
KR20210044822A (ko) 2021-04-23
KR102849047B1 (ko) 2025-08-22
CA3109192A1 (en) 2020-02-13
CN119080779A (zh) 2024-12-06
AU2019317625A1 (en) 2021-02-18
US20220348579A1 (en) 2022-11-03
JP2025037892A (ja) 2025-03-18
PH12021550187A1 (en) 2022-02-14

Similar Documents

Publication Publication Date Title
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
CO2021009806A2 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria sobre cdk2
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2024007220A2 (es) Compuestos que contienen heteroátomos y usos de estos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP18083519A (es) Inhibidores de bromodominios
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX391489B (es) Inhibidores heterociclicos de mct4.
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX2021013224A (es) Pirrolopiridinas sustituidas como inhibidores de jak.
CR20170021A (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo
UY31539A1 (es) Agentes antelminticos y su uso
GT201200111A (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
UY32554A (es) Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos
MX387969B (es) Composiciones y compuestos terapéuticos, y métodos para su uso.
CO2022000481A2 (es) Inhibidores de enzimas
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
CL2025003586A1 (es) Compuestos heterocíclicos y usos de estos
CL2019002877A1 (es) Compuestos de piridona y fungicidas agrícolas y hortícolas que los contienen como ingredientes activos.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio